Trial · NCT02132195

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

NCT02132195, Phase 3, Completed, Emory University; results first posted 2019-05-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome. Trials, record NCT02132195. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02132195

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NCT number: NCT02132195
Status: Completed
Phases: Phase 3
Enrollment: 31 participants, actual
Lead sponsor: Emory University
Conditions: Nephrotic Syndrome
Interventions: ACTH
First posted: 2014-05-07
Last updated: 2019-05-29
Results first posted: 2019-05-10

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Experienced a Relapse of Nephrotic Syndrome	6 months	Number of participants experienced a relapse of nephrotic syndrome during the initial 6 months of the study.
Secondary	Number of Participants Experiencing Relapses After Dose Reduction of ACTH	6 to 12 months	The dose of ACTH will be reduced by 50% after 6 months and the rate of relapse during this period will be evaluated.
Secondary	Number of Adverse Events	12 months	Adverse events will be collected (SAEs and AEs)

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants Experienced a Relapse of Nephrotic Syndrome	6 months	The primary outcome measure was accessed during the initial 6 months based on initial assignment, rescue therapy group was not part of the analysis.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Experiencing Relapses After Dose Reduction of ACTH	6 to 12 months	Three participants who completed 6 months of ACTH Full Dose therapy and then 6 months of Reduced Dose ACTH - inclusive of one subject initially randomized to ACTH and two subjects who received ACTH as rescue treatment	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Adverse Events	12 months	15 pts randomized to receive ACTH, and 16 pts randomized to No-treatment. 13 patients in No-treatment arm elected to receive ACTH as rescue therapy.	number of events	NUMBER

Source ClinicalTrials.gov

Results by group7

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants Experienced a Relapse of Nephrotic Syndrome	Adrenocorticotropic Hormone (ACTH)	14	Participants
Number of Participants Experienced a Relapse of Nephrotic Syndrome	No Treatment	15	Participants
Number of Participants Experiencing Relapses After Dose Reduction of ACTH	Adrenocorticotropic Hormone (ACTH)	0	Participants
Number of Participants Experiencing Relapses After Dose Reduction of ACTH	Rescue Therapy	0	Participants
Number of Adverse Events	Adrenocorticotropic Hormone (ACTH)	12	number of events
Number of Adverse Events	No Treatment	4	number of events
Number of Adverse Events	Rescue Therapy	17	number of events

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Initial Assignment	STARTED	Adrenocorticotropic Hormone (ACTH)	15
Initial Assignment	STARTED	No Treatment	16
Initial Assignment	STARTED	Rescue Therapy	0
Initial Assignment	COMPLETED	Adrenocorticotropic Hormone (ACTH)	1
Initial Assignment	COMPLETED	No Treatment	16
Initial Assignment	COMPLETED	Rescue Therapy	0
Initial Assignment	NOT COMPLETED	Adrenocorticotropic Hormone (ACTH)	14
Initial Assignment	NOT COMPLETED	No Treatment	0
Initial Assignment	NOT COMPLETED	Rescue Therapy	0
Rescue Therapy	STARTED	Adrenocorticotropic Hormone (ACTH)	0

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Flu and strep infections	Infections and infestations	Adrenocorticotropic Hormone (ACTH)	0	15	0
other	Flu and strep infections	Infections and infestations	No Treatment	0	16	0
other	Flu and strep infections	Infections and infestations	Rescue Therapy	3	13	3
other	Behavioral changes	Social circumstances	Adrenocorticotropic Hormone (ACTH)	2	15	2
other	Behavioral changes	Social circumstances	No Treatment	0	16	0
other	Behavioral changes	Social circumstances	Rescue Therapy	1	13	1
other	Sleep disturbances	Nervous system disorders	Adrenocorticotropic Hormone (ACTH)	2	15	2
other	Sleep disturbances	Nervous system disorders	No Treatment	0	16	0
other	Sleep disturbances	Nervous system disorders	Rescue Therapy	2	13	2
other	Increase in blood pressure	Vascular disorders	Adrenocorticotropic Hormone (ACTH)	1	15	2

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Adrenocorticotropic Hormone (ACTH)	0	15
Total, all-cause mortality	No Treatment	0	16
Total, all-cause mortality	Rescue Therapy	0	13
Total, other adverse events	Adrenocorticotropic Hormone (ACTH)	4	15
Total, other adverse events	No Treatment	2	16
Total, other adverse events	Rescue Therapy	9	13
Total, serious adverse events	Adrenocorticotropic Hormone (ACTH)	3	15
Total, serious adverse events	No Treatment	2	16
Total, serious adverse events	Rescue Therapy	2	13

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
39513526	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02132195

GET https://conductscience.org/api/trials/v1/NCT02132195/events?page=2

API reference For AI assistants